Gsk Stock Quote GSK - Stock Price, News, Charts, Message Board, Trades

Unlock more advanced trading tools

Join ADVFN today

Current Price

1,638.50

Bid

1,638.00

Ask

1,639.00

Volume

1,923,423

1,635.50 Day's Range 1,661.50

1,302.60 52 Week Range 1,719.80

Market Cap

67.602B

Previous Close

1,651.00

Open

1,656.50

Last Trade

116

1638.5

(AT)

Last Trade Time

Financial Volume

31,715,149p

VWAP

1,648.891

Average Volume (3m)

8,529,905

Shares Outstanding

4,117,033,438

Dividend Yield

3.54%

PE Ratio

13.72

Earnings Per Share (EPS)

1.2

Revenue

30.33B

Net Profit

4.93B

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.gsk.com

Headquarters

Middlesex, Gbr

Founded

1970

Gsk Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker GSK. The last closing price for Gsk was 1,651p. Over the last year, Gsk shares have traded in a share price range of 1,302.60p to 1,719.80p.

Gsk currently has 4,117,033,438 shares outstanding. The market capitalization of Gsk is £67.60 billion. Gsk has a price to earnings ratio (PE ratio) of 13.72.

GSK's Jemperli with chemotherapy accepted for priority review by FDA

GSK PLC on Wednesday said that the US Food & Drug Administration has accepted a supplemental biologics licence applic ...

GSK PLC US FDA accepts new indication filing for Jemperli

GSK PLC 24 April 2024 Issued: 24 April 2024, London UK US FDA accepts for priority review GSK's application for an expanded indication of Jemperli (dostarlimab) plus chemotherapy to...

GSK PLC Director/PDMR Shareholding

GSK PLC 19 April 2024 GSK plc (the 'Company') Transaction notification 1. Details of PDMR/person closely associated with them ('PCA') a) Name Emma Walmsley b) Position/status Chief...

GSK PLC Director/PDMR Shareholding

GSK PLC 17 April 2024 GSK plc (the 'Company') Transaction notification 1. Details of PDMR/person closely associated with them ('PCA') a) Name Emma Walmsley b) Position/status Chief Executive...

TOP NEWS: GSK hails data on Shingles vaccine and gonorrhoea treatment

GSK PLC on Wednesday reported new test data for its shingles vaccine and for a potential new oral treatment for a for ...

GSK PLC GSK announces additional EAGLE-1 results

GSK PLC 17 April 2024 Issued: 17 April 2024, London UK EAGLE-1 phase III data show potential for gepotidacin as a new oral treatment option for uncomplicated urogenital gonorrhoea (GC...

GSK PLC Results from long-term data relating to Shingrix

GSK PLC 17 April 2024 Issued: 17 April 2024, London UK New long-term data show Shingrix continues to provide high protection against shingles in adults aged 50 and over for more than a...

GSK PLC Amendment - Director/PDMR Shareholding

GSK PLC 16 April 2024 The following amendment has been made to the 'Director/PDMR Shareholding' announcement released on 15 April 2024 at 15:30 under RNS No 6703K: - A typographical...

GSK's latest meningitis vaccine accepted for review by US regulator

GSK PLC on Tuesday said it has made progress in the development of its newest candidate, which combines the strengths ...

GSK PLC FDA accepts GSK meningitis vaccine candidate file

GSK PLC 16 April 2024 Issued: 16 April 2024, London UK GSK's 5-in-1 meningococcal ABCWY vaccine candidate accepted for regulatory review by US FDA · Vaccine candidate provides broad...

GSK's Jemperli with chemotherapy accepted for priority review by FDA

GSK PLC on Wednesday said that the US Food & Drug Administration has accepted a supplemental biologics licence applic ...

GSK PLC US FDA accepts new indication filing for Jemperli

GSK PLC 24 April 2024 Issued: 24 April 2024, London UK US FDA accepts for priority review GSK's application for an expanded indication of Jemperli (dostarlimab) plus chemotherapy to...

GSK PLC Director/PDMR Shareholding

GSK PLC 19 April 2024 GSK plc (the 'Company') Transaction notification 1. Details of PDMR/person closely associated with them ('PCA') a) Name Emma Walmsley b) Position/status Chief...

GSK PLC Director/PDMR Shareholding

GSK PLC 17 April 2024 GSK plc (the 'Company') Transaction notification 1. Details of PDMR/person closely associated with them ('PCA') a) Name Emma Walmsley b) Position/status Chief Executive...

TOP NEWS: GSK hails data on Shingles vaccine and gonorrhoea treatment

GSK PLC on Wednesday reported new test data for its shingles vaccine and for a potential new oral treatment for a for ...

GSK PLC GSK announces additional EAGLE-1 results

GSK PLC 17 April 2024 Issued: 17 April 2024, London UK EAGLE-1 phase III data show potential for gepotidacin as a new oral treatment option for uncomplicated urogenital gonorrhoea (GC...

GSK PLC Results from long-term data relating to Shingrix

GSK PLC 17 April 2024 Issued: 17 April 2024, London UK New long-term data show Shingrix continues to provide high protection against shingles in adults aged 50 and over for more than a...

GSK PLC Amendment - Director/PDMR Shareholding

GSK PLC 16 April 2024 The following amendment has been made to the 'Director/PDMR Shareholding' announcement released on 15 April 2024 at 15:30 under RNS No 6703K: - A typographical...

GSK's latest meningitis vaccine accepted for review by US regulator

GSK PLC on Tuesday said it has made progress in the development of its newest candidate, which combines the strengths ...

GSK PLC FDA accepts GSK meningitis vaccine candidate file

GSK PLC 16 April 2024 Issued: 16 April 2024, London UK GSK's 5-in-1 meningococcal ABCWY vaccine candidate accepted for regulatory review by US FDA · Vaccine candidate provides broad...

GSK PLC Director/PDMR Shareholding

GSK PLC 15 April 2024 GSK plc (the 'Company') Transaction notification 1. Details of PDMR/person closely associated with them ('PCA') a) Name Emma Walmsley b) Position/status Chief Executive...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	40.5	2.53441802253	1598	1661.5	1575	5726419	1611.11187162	DE
4	-61.5	-3.61764705882	1700	1713	1575	6810423	1637.38131229	DE
12	103.5	6.74267100977	1535	1719.8	1514.8	8529905	1652.66644324	DE
26	193.1	13.3596236336	1445.4	1719.8	1376	7927287	1560.73570089	DE
52	161.3	10.9193067966	1477.2	1719.8	1302.6	7542918	1493.23063736	DE
156	298.3	22.2578719594	1340.2	1824.4	1283.2	8631186	1510.60267968	DE
260	78.5	5.03205128205	1560	1857	1190.8	8913626	1523.91775402	DE

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
CSSEChicken Soup for the Soul Entertainment Inc	$ 0.4379 (187.52%)	122.46M
BOFBranchOut Food Inc	$ 1.975 (68.80%)	64.93M
AMSTAmesite Inc	$ 3.24 (62.00%)	61.58M
PREPrenetics Global Ltd	$ 6.67 (45.95%)	1.81M
LICNLichen China Limited	$ 0.8025 (43.30%)	11.99M
GCTKGlucoTrack Inc	$ 0.45 (-40.79%)	1.05M
NCINeo Concept International Group Holdings Ltd	$ 5.63 (-40.74%)	1.1M
EVOEvotec SE	$ 5.22 (-31.76%)	753.97k
ATXIAvenue Therapeutics Inc	$ 0.094 (-29.85%)	7.07M
HUBCWHub Cyber Security Ltd	$ 0.016 (-27.27%)	8.01k
CSSEChicken Soup for the Soul Entertainment Inc	$ 0.4379 (187.52%)	122.46M
TSLATesla Inc	$ 161.27 (11.47%)	99.62M
BOFBranchOut Food Inc	$ 1.975 (68.80%)	64.93M
AMSTAmesite Inc	$ 3.24 (62.00%)	61.58M
SQQQProShares UltraPro Short QQQ	$ 11.855 (-0.46%)	59.29M